Eagle Pharmaceuticals CEO Scott Tarriff resigns; Chairman Michael Graves named Interim Executive Chairman

EAGLE PHARMACEUTICALS, INC.

Scott Tarriff resigns as President, CEO, and Director effective Nov 27, 2023; will serve as consultant starting Jan 1, 2024.
Michael Graves appointed Interim Executive Chairman and Interim Principal Executive Officer; CEO search initiated.
Board reduced from seven to six members; committee assignments realigned.
Tarriff receives severance: 18-month base salary lump sum, target bonus, COBRA for 18 months, and $20k/month consulting retainer.
Equity vesting acceleration for time-vesting awards; performance-vesting 2021 PSUs remain eligible during consulting period.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Scott Tarriff

President, Chief Executive Officer and Director

EAGLE PHARMACEUTICALS, INC.

Effective: 2023-11-27
Successor: Michael Graves
Filed: November 29, 2023, 6:59 PM ET

On November 27, 2023, Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals, Inc. (the “Company”), resigned and retired from his positions with the Company as President, Chief Executive Officer, Principal Executive Officer and Director on the Company’s Board of Directors (the “Board”), effective immediately.

Role change (interim)

Michael Graves

Interim Executive Chairman and Interim Principal Executive Officer

EAGLE PHARMACEUTICALS, INC.

Effective: 2023-11-27
Filed: November 29, 2023, 6:59 PM ET

Michael Graves, Chairman of the Board, was appointed Interim Executive Chairman of the Board and Interim Principal Executive Officer, effective immediately, until such time as a new Chief Executive Officer commences employment or such other date determined by the Board or upon his earlier resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Tarriff resigned as President, Chief Executive Officer and Director at EAGLE PHARMACEUTICALS, INC..

Action: resigned
Role: President, Chief Executive Officer and Director

Exact text from the filing

On November 27, 2023, Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals, Inc. (the “Company”), resigned and retired from his positions with the Company as President, Chief Executive Officer, Principal Executive Officer and Director on the Company’s Board of Directors (the “Board”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Graves was appointed as Interim Executive Chairman and Interim Principal Executive Officer at EAGLE PHARMACEUTICALS, INC..

Action: appointed
Role: Interim Executive Chairman and Interim Principal Executive Officer

Exact text from the filing

Michael Graves, Chairman of the Board, was appointed Interim Executive Chairman of the Board and Interim Principal Executive Officer, effective immediately, until such time as a new Chief Executive Officer commences employment or such other date determined by the Board or upon his earlier resignation.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-23-121842

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.